TAPUR Trial
Phase 2
4,200
about 13 years
12+
174 sites in AL, AZ, CA +25
What this study is about
This trial is testing different treatments for advanced cancer. The goal is to learn from real-world prescribing practices and predict which patients will benefit most from targeted therapies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Tucatinib plus Trastuzumab Subcutaneous (SC)
- 2.Take Abemaciclib
- 3.Take Atezolizumab and PHESGO
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abemaciclib, atezolizumab, cobimetinib, dabrafenib, Antineoplastic Agent [TC] (HER2/Neu/cerbB2 Antagonists), futibatinib, ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells), nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
oral (Oral Tablet), injection (Injection), oral (Oral Capsule), infusion, oral, injection, intravenous
Primary: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Secondary: Overall survival (OS)
Oncology